Skip to main content
Thorax logoLink to Thorax
. 2000 Nov;55(11):962–963. doi: 10.1136/thorax.55.11.962

Resource implications of patients with multidrug resistant tuberculosis

V White 1, J Moore-Gillon 1
PMCID: PMC1745633  PMID: 11050268

Abstract

BACKGROUND—Multidrug resistant tuberculosis (MDR TB) requires a complex drug regimen and lengthy multidisciplinary care. The financial cost of successful management of each case is potentially large.
METHODS—The costs of managing nine HIV negative patients with pulmonary MDR TB were compared with 18 age group and ethnicity matched controls with fully sensitive disease. Calculations included: cost of outpatient visits and inpatient stays including negative pressure isolation; costs of drug provision and toxicity monitoring; costs of additional procedures and multidisciplinary referrals.
RESULTS—The mean cost of managing a case of pulmonary MDR TB was in excess of £60 000 and for sensitive disease it was £6040.
CONCLUSIONS—Clinicians and healthcare commissioning authorities may both be underestimating the costs of managing MDR TB, and accordingly the consequences for units dealing with such cases may be serious. Funding of care for MDR TB in the UK requires strategic decisions at regional or governmental level.



Full Text

The Full Text of this article is available as a PDF (72.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Iseman M. D. Treatment of multidrug-resistant tuberculosis. N Engl J Med. 1993 Sep 9;329(11):784–791. doi: 10.1056/NEJM199309093291108. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES